ZZW-115 hydrochloride is a potent NUPR1 inhibitor, with a K_d of 2.1 μM. ZZW-115 hydrochloride induces tumor cell death by necroptosis and apoptosis. Anticancer activity^[1][2].

ZZW-115 hydrochloride (0.1-33 μM; 72 hours) is efficient in killing cancer cells, with an IC₅₀ in the range of 0.84 μM (ANOR) to 4.93 μM (HN14)^[1].
ZZW-115 hydrochloride (0-100 μM; 24-72 hours) is efficient to kill these tumor cells with an IC₅₀ in the range of 0.42 μM (Hep2G cells) to 7.75 μM (SaOS-2 cells)^[1].
ZZW-115 hydrochloride induces pancreatic cell death by necrosis and apoptosis. ZZW-115 hydrochloride treatment induces a decrease in ATP production and induces a ROS overproduction^[1].
LDH release is significantly higher in ZZW-115 hydrochloride-treated cells (MiaPaCa-2, 02-063, LIPC, Foie8b, and HN14 cells) than in control cells in a concentration-dependent manner. Similarly, caspase 3/7 activity is also greater in ZZW-115 hydrochloride-treated cells. These experiments demonstrated that ZZW-115 hydrochloride exerted both pronecrotic and proapoptotic effects^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

ZZW-115 hydrochloride (0.5-5 mg/kg; injection; daily for 30 days) inhibits the growth of pancreatic xenografted tumors^[1].
ZZW-115 hydrochloride (5 mg/kg for 30 days; immunocompetent C57BL/6 mice were orthotopically implanted with Panc02 cells) treatment shows the tumor size is almost unmeasurable in some cases^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

573.97

C₂₄H₃₄Cl₃F₃N₄S

10122-45-9

Room temperature in continental US; may vary elsewhere.

4°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

DMSO : 83.33 mg/mL (145.18 mM; Need ultrasonic)

H₂O : 60 mg/mL (104.54 mM; Need ultrasonic)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

  Solubility: ≥ 6.25 mg/mL (10.89 mM); Clear solution

  此方案可获得 ≥ 6.25 mg/mL (10.89 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 62.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

  将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

• 2.

  请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

  Solubility: ≥ 6.25 mg/mL (10.89 mM); Clear solution

  此方案可获得 ≥ 6.25 mg/mL (10.89 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 62.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

  将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明

• [1]. Santofimia-Castaño P, et al. Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis. J Clin Invest. 2019;129(6):2500-2513. Published 2019 Mar 28.

  [2]. Santofimia-Castaño P, et al. Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma. Cells. 2019;8(11):1453. Published 2019 Nov 17.